Numab Therapeutics AG

About Numab Therapeutics AG

Numab Therapeutics AG is a biopharmaceutical company focused on establishing a leading platform for next-generation plug & play multispecific therapeutics. The company aims to advance a proprietary pipeline of immunology and immuno-oncology drugs, developing first- and best-in-class high-impact therapeutics to overcome limitations of existing approaches and improve patient outcomes through innovative drug discovery and engineering technologies.

Products & Services

NM26:A bispecific antibody targeting IL-4Rα and IL-31 for the treatment of atopic dermatitis and other type 2 inflammatory disorders, designed for faster onset and improved efficacy with subcutaneous administration.

ND081:A multi-specific antibody for the treatment of inflammatory bowel disease, under preclinical development with regional collaboration.

NM32:A first-in-class half-life-enhanced T-cell engager targeting ROR1 for solid tumors and hematological malignancies, initiated in Phase 1 clinical study.

λ-Cap™ and MATCH™ Platforms:Proprietary platforms designed to create differentiated multispecific antibody-based therapeutics with tailored pharmacokinetic properties for improved potency, stability, and safety.

Specialties

Multispecific antibody-based therapeutics Immunology Immuno-oncology Drug discovery and engineering technologies Atopic dermatitis treatment Inflammatory bowel disease treatment Solid tumor and hematological malignancy treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C Extension T: - FT: Series C Extension	A: 55000000 MR: - FA: CHF 50 million FAN: 55000000	D: 2025-01-09 FD: 2025-01-09	8 investors

Series C Extension Latest

2025-01-09

$55.0M

8 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Mireia Gómez-Angelats

Chief Business Officer

T

Tea Gunde

VP Scientific Evaluation

R

Roland Helfenstein

Chief Financial Officer

S

Sebastian Meyer

Chief Operating Officer

J

James Singleton

General Counsel

D

Daniel Snell

Senior VP Research and Preclinical Development

View 21 more team members with Pro

Unlock Full Team Directory

Recent News